PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32429320-1	2020	Rigosertib, via reactive oxygen species (ROS), stimulates cJun N-terminal kinases 1/2 (JNK1/2), which inactivate RAS/RAF signaling and thereby inhibit growth and survival of tumor cells.	Reactive Oxygen Species	16-39	mitogen-activated protein kinase 8	Homo sapiens	58-85	
32429320-1	2020	Rigosertib, via reactive oxygen species (ROS), stimulates cJun N-terminal kinases 1/2 (JNK1/2), which inactivate RAS/RAF signaling and thereby inhibit growth and survival of tumor cells.	Reactive Oxygen Species	16-39	mitogen-activated protein kinase 8	Homo sapiens	87-93	
32429320-1	2020	Rigosertib, via reactive oxygen species (ROS), stimulates cJun N-terminal kinases 1/2 (JNK1/2), which inactivate RAS/RAF signaling and thereby inhibit growth and survival of tumor cells.	Reactive Oxygen Species	41-44	mitogen-activated protein kinase 8	Homo sapiens	58-85	
32429320-1	2020	Rigosertib, via reactive oxygen species (ROS), stimulates cJun N-terminal kinases 1/2 (JNK1/2), which inactivate RAS/RAF signaling and thereby inhibit growth and survival of tumor cells.	Reactive Oxygen Species	41-44	mitogen-activated protein kinase 8	Homo sapiens	87-93	
32429320-2	2020	JNK1/2 are not only regulated by ROS-they in turn can also control ROS production.	Reactive Oxygen Species	33-36	mitogen-activated protein kinase 8	Homo sapiens	0-6	
32429320-2	2020	JNK1/2 are not only regulated by ROS-they in turn can also control ROS production.	Reactive Oxygen Species	67-70	mitogen-activated protein kinase 8	Homo sapiens	0-6	
32429320-4	2020	Here, we provide evidence that establishes p66Shc, an oxidoreductase, as a JNK1/2 effector downstream of Rigosertib-induced ROS production, DNA damage, and cell death.	Reactive Oxygen Species	124-127	mitogen-activated protein kinase 8	Homo sapiens	75-81